An unusual hidden secret of a Meckel's diverticulum: a rare case of small bowel adenocarcinoma.

IF 1.3 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY

Acta gastro-enterologica Belgica Pub Date : 2025-01-01 DOI:10.51821/88.1.13489

T Hendrickx, F Van Herpe, A D'Hoore, R C Dresen, J Sabino

引用次数: 0

Abstract

A Meckel's diverticulum (MD) is the most prevalent congenital anomaly of the gastro-intestinal tract and the life-long risk for complications is estimated to be around 4%, mostly resulting in bleeding, obstruction, diverticulitis or intussusception. Although rare, about 3.1-5.1% of the complications are due to malignant evolution of the MD. Case: We present a 50-year old patient with progressive subobstructive symptoms leading the diagnosis of a complicated MD. Peroperative findings were suggestive for malignancy and the histopathological samples confirmed the presence of a metastatic adenocarcinoma, arising from the MD. Conclusion: This case illustrates a rare, malignant complication of a MD. This finding is of utmost clinical importance because the diagnosis may be challenging and early detection may improve the outcome of these patients. The clinician should be aware that malignant evolution of a MD exists and should be excluded in complicated cases.

查看原文本刊更多论文

梅克尔氏憩室（MD）是胃肠道最常见的先天性畸形，据估计，终身并发症的风险约为 4%，主要导致出血、梗阻、憩室炎或肠套叠。尽管很少见，但约有 3.1-5.1%的并发症是由于 MD 的恶性演变引起的。病例：我们接诊了一名 50 岁的患者，患者出现进行性梗阻下症状，被诊断为复杂性多发性肠梗阻。围手术期检查结果提示为恶性肿瘤，组织病理学样本证实其为MD转移性腺癌。结论：本病例说明了一种罕见的 MD 恶性并发症。这一发现具有极其重要的临床意义，因为诊断可能具有挑战性，而早期发现可改善这些患者的预后。临床医生应该意识到多发性骨髓瘤的恶性演变是存在的，在复杂病例中应排除这一可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta gastro-enterologica Belgica Medicine-Gastroenterology

CiteScore

2.30

自引率

20.00%

发文量

期刊介绍： The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.